• Garvan Institute secures $3 million MRFF grant for pancreatic cancer studies
• One study will evaluate Syntara's amsulostat with standard-of-care chemotherapy
• Syntara to provide drug supply and expertise, no cash funding required

Syntara Limited (ASX: SNT) announced that the Garvan Institute of Medical Research in Sydney has been awarded a $3 million grant under the Australian Government's Medical Research Future Fund (MRFF) to conduct two multicentre Australian clinical studies in advanced pancreatic cancer. One of the studies will evaluate Syntara's investigational anti-fibrotic LOX inhibitor amsulostat (SNT-5505) in combination with standard-of-care chemotherapy. Under the collaboration, Syntara will supply the drug in addition to scientific and clinical expertise to support the program, but will not be required to provide cash funding. The inclusion of amsulostat in this MRFF-funded clinical program builds on preclinical research led by the Garvan Institute, which demonstrated that targeting tumour fibrosis can improve chemotherapy penetration and effectiveness in pancreatic tumours. The MRFF-funded studies are expected to commence recruitment in mid-2026, enrolling patients with advanced pancreatic cancer across leading cancer centres in New South Wales. The studies will also incorporate a precision medicine strategy, including deep molecular and genetic profiling, to identify biomarkers and patient subgroups most likely to benefit from the treatment approach.

The initiation of the pancreatic cancer study later this year adds to an already rich clinical development program in 2026, which will see the SNT-4728 study in iRBD deliver top line results in Q2 2026, followed by two amsulostat studies in MDS and two skin scarring studies all due to report data later this year.